Grants and Contributions:
Title:
MNC Collab - PACAAL - In vivo potency assessment of candidate antibodies (LX-96) for AL amyloidosis
Agreement Number:
1027009
Agreement Value:
$73,524.00
Agreement Date:
Dec 4, 2024 - Jul 31, 2025
Description:
As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly for the treatment of kappa light chain amyloidosis. After in vivo evaluation of the candidates, we will nominate a development candidate to move forward in IND-enabling studies.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 0B7
Reference Number:
172-2024-2025-Q4-1027009
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
758832877
Recipient Type:
For-profit organization
Recipient's Legal Name:
Paradox Immunotherapeutics Incorporated
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171